Age adjusting severity scores for Anderson-Fabry Disease

Molecular Genetics and Metabolism

Volumn 101, Issue 2-3, 2010, Pages 219-227

  Hughes, D A ^a   Ramaswami, U ^b   Barba Romero, M A ^c   Deegan, P ^b  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

Author keywords

Age adjusted; Clinical genetics; Fabry; Score; Severity

Indexed keywords

ALPHA GALACTOSIDASE;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CHILD; CLINICAL FEATURE; DISEASE SEVERITY; FABRY DISEASE; FEMALE; GENDER; GENOTYPE; HUMAN; LYSOSOME STORAGE DISEASE; MAINZ SEVERITY SCORE INDEX; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGE FACTORS; AGED; CHILD; CHILD, PRESCHOOL; DATABASES, FACTUAL; FABRY DISEASE; FEMALE; HUMANS; INFANT; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

EID: 77957225816     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2010.06.002     Document Type: Article

References (38)

1. Kint J.A. Fabry's disease: alpha-galactosidase deficiency. Science Feb 27 1970, 167(922):1268-1269.
2. MacDermot K.D., Holmes A., Miners A.H. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J. Med. Genet. Nov 2001, 38(11):750-760.
3. Mehta A., Ricci R., Widmer U., Dehout F., Garcia d.L., Kampmann C., Linhart A., Sunder-Plassmann G., Ries M., Beck M. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur. J. Clin. Invest. Mar 2004, 34(3):236-242.
4. Deegan P.B., Baehner A.F., Barba Romero M.A., Hughes D.A., Kampmann C., Beck M. Natural history of Fabry disease in females in the Fabry Outcome Survey. J. Med. Genet. Apr 2006, 43(4):347-352.
5. Whybra C., Kampmann C., Willers I., Davies J., Winchester B., Kriegsmann J., Bruhl K., Gal A., Bunge S., Beck M. Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes. J. Inherit. Metab. Dis. Dec 2001, 24(7):715-724.
6. MacDermot K.D., Holmes A., Miners A.H. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J. Med. Genet. Nov 2001, 38(11):769-775.
7. Ries M., Gupta S., Moore D.F., Sachdev V., Quirk J.M., Murray G.J., Rosing D.R., Robinson C., Schaefer E., Gal A., Dambrosia J.M., Garman S.C., Brady R.O., Schiffmann R. Pediatric Fabry disease. Pediatrics Mar 2005, 115(3):e344-e355.
8. Ramaswami U., Whybra C., Parini R., Pintos-Morell G., Mehta A., Sunder-Plassmann G., Widmer U., Beck M. Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey. Acta Paediatr. Jan 2006, 95(1):86-92.
9. Meikle P.J., Grasby D.J., Dean C.J., Lang D.L., Bockmann M., Whittle A.M., Fietz M.J., Simonsen H., Fuller M., Brooks D.A., Hopwood J.J. Newborn screening for lysosomal storage disorders. Mol. Genet. Metab. Aug 2006, 88(4):307-314.
10. Spada M., Pagliardini S., Yasuda M., Tukel T., Thiagarajan G., Sakuraba H., Ponzone A., Desnick R.J. High incidence of later-onset Fabry disease revealed by newborn screening. Am. J. Hum. Genet. Jul 2006, 79(1):31-40.
11. Sachdev B., Takenaka T., Teraguchi H.L., Tei C., Lee P., McKenna W.J., Elliott P.M. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation Mar 26 2002, 105(12):1407-1411.
12. Nakao S., Kodama C., Takenaka T., Tanaka A., Yasumoto Y., Yoshida A., Kanzaki T., Enriquez A.L., Eng C.M., Tanaka H., Tei C., Desnick R.J. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype. Kidney Int. Sep 2003, 64(3):801-807.
13. Nakao S., Takenaka T., Maeda M., Kodama C., Tanaka A., Tahara M., Yoshida A., Kuriyama M., Hayashibe H., Sakuraba H. An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N. Engl. J. Med. Aug 3 1995, 333(5):288-293.
14. Rolfs A., Bottcher T., Zschiesche M., Morris P., Winchester B., Bauer P., Walter U., Mix E., Lohr M., Harzer K., Strauss U., Pahnke J., Grossmann A., Benecke R. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet Nov 19 2005, 366(9499):1794-1796.
15. Beck M., Ricci R., Widmer U., Dehout F., de Lorenzo A.G., Kampmann C., Linhart A., Sunder-Plassmann G., Houge G., Ramaswami U., Gal A., Mehta A. Fabry disease: overall effects of agalsidase alfa treatment. Eur. J. Clin. Invest. Dec 2004, 34(12):838-844.
16. Hoffmann B., Garcia d.L., Mehta A., Beck M., Widmer U., Ricci R. Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey). J. Med. Genet. Mar 2005, 42(3):247-252.
17. Hoffmann B., Reinhardt D., Koletzko B. Effect of enzyme-replacement therapy on gastrointestinal symptoms in Fabry disease. Eur. J. Gastroenterol. Hepatol. Oct 2004, 16(10):1067-1069.
18. Dehout F., Roland D., Treille d.G., Guillaume B., Van Maldergem L. Relief of gastrointestinal symptoms under enzyme replacement therapy [corrected] in patients with Fabry disease. J. Inherit. Metab. Dis. 2004, 27(4):499-505.
19. Dehout F., Schwarting A., Beck M., Mehta A., Ricci R., Widmer U. Effects of enzyme replacement therapy with agalsidase alfa on glomerular filtration rate in patients with Fabry disease: preliminary data. Acta Paediatr. Suppl. Dec 2003, 92(443):14-15.
20. Spinelli L., Pisani A., Sabbatini M., Petretta M., Andreucci M.V., Procaccini D., Lo S.N., Federico S., Cianciaruso B. Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease. Clin. Genet. Aug 2004, 66(2):158-165.
21. Hughes D.A., Elliott P.M., Shah J., Zuckerman J., Coughlan G., Brookes J., Mehta A.B. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomized, double-blind, placebo-controlled clinical trial of agalsidase-alfa. Heart Feb 2008, 94(2):153-158.
22. Ramaswami U., Wendt S., Pintos-Morell G., Parini R., Whybra C., Leon Leal J.A., Santus F., Beck M. Enzyme replacement therapy with agalsidase alfa in children with Fabry disease. Acta Paediatr. Jan 2007, 96(1):122-127.
23. Ries M., Clarke J.T., Whybra C., Timmons M., Robinson C., Schlaggar B.L., Pastores G., Lien Y.H., Kampmann C., Brady R.O., Beck M., Schiffmann R. Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease. Pediatrics Sep 2006, 118(3):924-932.
24. Eng C.M., Guffon N., Wilcox W.R., Germain D.P., Lee P., Waldek S., Caplan L., Linthorst G.E., Desnick R.J. Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease. N. Engl. J. Med. Jul 5 2001, 345(1):9-16.
25. Schiffmann R., Ries M., Timmons M., Flaherty J.T., Brady R.O. Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol. Dial. Transplant. Feb 2006, 21(2):345-354.
26. Wraith J.E., Tylki-Szymanska A., Guffon N., Lien Y.H., Tsimaratos M., Vellodi A., Germain D.P. Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease. J. Pediatr. Apr 2008, 152(4):563-570. 570.
27. Schiffmann R., Kopp J.B., Austin H.A., Sabnis S., Moore D.F., Weibel T., Balow J.E., Brady R.O. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA Jun 6 2001, 285(21):2743-2749.
28. Eng C.M., Banikazemi M., Gordon R.E., Goldman M., Phelps R., Kim L., Gass A., Winston J., Dikman S., Fallon J.T., Brodie S., Stacy C.B., Mehta D., Parsons R., Norton K., O'Callaghan M., Desnick R.J. A phase 1/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am. J. Hum. Genet. Mar 2001, 68(3):711-722.
29. Hughes D.A., Ramaswam U., Elliott P., Deegan P., Lee P., Waldek S., Apperley G., Cox T., Mehta A.B. Guidelines for the Diagnosis and Management of Anderson-Fabry Disease. Publications and statistics 2005, Available from: URL: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4118404.
30. Eng C.M., Germain D.P., Banikazemi M., Warnock D.G., Wanner C., Hopkin R.J., Bultas J., Lee P., Sims K., Brodie S.E., Pastores G.M., Strotmann J.M., Wilcox W.R. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet. Med. Sep 2006, 8(9):539-548.
31. Connock M., Juarez-Garcia A., Frew E., Mans A., Dretzke J., Fry-Smith A., Moore D. A systematic review of the clinical effectiveness and cost-effectiveness of enzyme replacement therapies for Fabry's disease and mucopolysaccharidosis type 1. Health Technol. Assess. Jun 2006, 10(20). iii-iv, ix-113.
32. Whybra C., Kampmann C., Krummenauer F., Ries M., Mengel E., Miebach E., Baehner F., Kim K., Bajbouj M., Schwarting A., Gal A., Beck M. The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin. Genet. Apr 2004, 65(4):299-307.
33. Hughes D.A. Early therapeutic intervention in females with Fabry disease?. Acta Paediatr. Suppl. Apr 2008, 97(457):41-47.
34. Giannini E.H., Mehta A.B., Hilz M.J., Beck M., Bichet D.G., Brady R.O., West M., Germain D.P., Wanner C., Waldek S., Clarke J.T., Mengel E., Strotmann J.M., Warnock D.G., Linhart A. A validated disease severity scoring system for Fabry disease. Mol. Genet. Metab. Mar 2010, 99(3):283-290.
35. Schaefer E., Mehta A., Gal A. Genotype and phenotype in Fabry disease: analysis of the Fabry Outcome Survey. Acta Paediatr. Suppl. Mar 2005, 94(447):87-92.
36. Ashley G.A., Shabbeer J., Yasuda M., Eng C.M., Desnick R.J. Fabry disease: twenty novel alpha-galactosidase A mutations causing the classical phenotype. J. Hum. Genet. 2001, 46(4):192-196.
37. Ashton-Prolla P., Tong B., Shabbeer J., Astrin K.H., Eng C.M., Desnick R.J. Fabry disease: twenty-two novel mutations in the alpha-galactosidase A gene and genotype/phenotype correlations in severely and mildly affected hemizygotes and heterozygotes. J. Investig. Med. Jul 2000, 48(4):227-235.
38. Ashton-Prolla P., Ashley G.A., Giugliani R., Pires R.F., Desnick R.J., Eng C.M. Fabry disease: comparison of enzymatic, linkage, and mutation analysis for carrier detection in a family with a novel mutation (30delG). Am. J. Med. Genet. Jun 11 1999, 84(5):420-424.